Analysis of cumulative probabilities shows that the efficacy of 5HT3 antagonist prophylaxis is not maintained

Journal of Clinical Oncology

Volumn 14, Issue 2, 1996, Pages 644-651

  de Wit, R ^a   Schmitz, P I ^a   Verweij, J ^a   de Boer Dennert, M ^a   de Mulder, P H ^a   Planting, A S ^a   van der Burg, M E ^a   Stoter, G ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; SEROTONIN 3 ANTAGONIST; TROPISETRON;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HEAD AND NECK CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; MESOTHELIOMA; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROBABILITY; STATISTICAL ANALYSIS; STATISTICAL MODEL; UTERINE CERVIX CARCINOMA; VOMITING;

EID: 0030032847     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.2.644     Document Type: Article

References (24)

1. Coates A, Abraham S, Kaye SB, et al: On the receiving end patients perception of the side effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19:203-208, 1983
2. Marty M, Pouillait P, Scholl S, et al: Comparison of the 5-hydroxytryptamine, (serotonin) antagonist ondansetron (GR38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 322:816-821, 1990
3. Mulder de PHM, Seynaeve C, Vermorken JB, et al: Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 113:834-840, 1990
4. Hainsworth J, Harvey W, Pendergrass K, et al: A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol 9:721-728, 1991
5. Blijham GH: Does granisetron remain effective over multiple cycles? Eur J Cancer 28A (S1):S17-S21, 1992 (suppl)
6. Soukop M, McQuade B, Hunter E, et al: Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology 49:295-304, 1992
7. Sorbe B: Tropisetron in the prevention of chemotherapy-induced nausea and vomiting: The Nordic experience. Ann Oncol 4:S39-S42, 1993 (suppl 3)
8. Wet de M, Falkson G, Rapoport BL: Repeated use of granisetron in patients receiving cytostatic agents. Cancer 71:4043-4049, 1993
9. Planting A, Stoter G, Verweij J: Phase II study of a short course of weekly cisplatin in locally advanced and recurrent squamous cell carcinoma of the head and neck. Proc Am Assoc Cancer Res 33:225, 1992 (abstr)
10. Planting A, Splinter T, de Boer-Dennert M, et al: Phase II study of a short course of weekly cisplatin combined with oral etoposide in non small cell lung cancer. Proc Am Soc Clin Oncol 12:353, 1993 (abstr)
11. Planting A, Goey S, de Boer-Dennert M, et al: Phase II study of a short course of weekly cisplatin combined with oral etoposide in pleural mesothelioma. Eur J Cancer 29A:S184, 1993 (suppl 6, abstr)
12. Lee CR, Plosker GL, McTavish D: Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic. Drugs 46:925-943, 1993
13. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
14. Ingelfinger JA, Mosteller F, Thibodeau LA, et al: Revising the estimated probability of disease, in Ingelfinger JA, Mosteller F, Thibodeau LA, et al (eds): Biostatistics in Clinical Medicine. New York, NY, Macmillan, 1983, pp 10-16
15. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, Wiley, 1980, p 15
16. Beck JR, Panker SG: The Markov process in medical prognosis. Med Decision Making 3:419-458, 1983
17. Roila F, Tonato M, Basurto C, et al: Protection from nausea and vomiting in cisplatin-treated patients: High-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: A study of the Italian Oncology Group for Clinical Research. J Clin Oncol 7:1693-1700, 1989
18. Martin M, Diaz-Rubio E, Casado E, et al: Progressive loss of antiemetic efficacy during subsequent courses of chemotherapy. Eur J Cancer 28:430-432, 1992
19. Italian Group for Antiemetic Research: Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy. J Clin Oncol 11:2396-2404, 1993
20. Kris M, Gralla RJ, Tyson LB, et al: Controlling delayed vomiting: Double blind randomized trial comparing placebo, dexamethasone alone and metoclopramide and dexamethasone in patients receiving cisplatin. J Clin Oncol 7:108-114, 1989
21. Kris MG, Tyson LB, Clark RA, et al: Oral ondansetron for the control of delayed emesis after cisplatin. Cancer 70:1012-1016, 1992
22. Gandara DR, Harvey WH, Monaghan GG, et al: The delayedemesis syndrome from cisplatin: Phase III evaluation of ondansetron versus placebo. Semin Oncol 19:67-71, 1992 (suppl 10)
23. Hamilton LC: Bootstrap methods, in Hamilton LC (ed): Regression With Graphics. Pacific Grove, CA, Brooks-Cole, 1992, pp 313-325
24. Bootstrap Sampling and Estimation, in Computing Resource Center. Stata Reference Manual, vol 2, Release 3 (ed 5). College Station, TX, Stata Corporation, 1992, pp 163-166